Health & Environmental Research Online (HERO)


Print Feedback Export to File
7033363 
Journal Article 
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics 
Feng, X; Sureda, A; Jafari, S; Memariani, Z; Tewari, D; Annunziata, G; Barrea, L; Hassan, STS; Šmejkal, K; Malaník, M; Sychrová, A; Barreca, D; Ziberna, L; Mahomoodally, MF; Zengin, G; Xu, S; Nabavi, SM; Shen, AZ; , 
2019 
Theranostics
ISSN: 1838-7640 
IVYSPRING INT PUBL 
LAKE HAVEN 
1923-1951 
English 
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.